JPMorgan Chase & Co. Sells 11,072 Shares of Anika Therapeutics, Inc. (NASDAQ:ANIK)

JPMorgan Chase & Co. cut its position in Anika Therapeutics, Inc. (NASDAQ:ANIK) by 41.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,509 shares of the biotechnology company’s stock after selling 11,072 shares during the quarter. JPMorgan Chase & Co. owned about 0.11% of Anika Therapeutics worth $383,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently made changes to their positions in the company. Eastern Bank purchased a new stake in shares of Anika Therapeutics in the third quarter worth $28,000. Quest Partners LLC raised its holdings in shares of Anika Therapeutics by 115.8% in the 3rd quarter. Quest Partners LLC now owns 6,904 shares of the biotechnology company’s stock valued at $171,000 after acquiring an additional 3,705 shares in the last quarter. Atria Investments Inc purchased a new stake in shares of Anika Therapeutics in the 3rd quarter valued at about $218,000. SG Americas Securities LLC boosted its position in shares of Anika Therapeutics by 43.1% during the 3rd quarter. SG Americas Securities LLC now owns 9,485 shares of the biotechnology company’s stock valued at $234,000 after acquiring an additional 2,858 shares during the last quarter. Finally, Cornercap Investment Counsel Inc. purchased a new position in shares of Anika Therapeutics during the third quarter worth about $238,000. 91.53% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ANIK has been the subject of several research analyst reports. Barrington Research dropped their target price on shares of Anika Therapeutics from $37.00 to $25.00 and set an “outperform” rating for the company in a research report on Friday, November 1st. StockNews.com cut shares of Anika Therapeutics from a “buy” rating to a “hold” rating in a research report on Monday, November 4th.

Anika Therapeutics Trading Up 1.1 %

Shares of Anika Therapeutics stock opened at $16.93 on Thursday. The business’s 50-day moving average price is $16.68 and its 200-day moving average price is $21.61. The firm has a market capitalization of $248.02 million, a PE ratio of -2.55 and a beta of 0.90. Anika Therapeutics, Inc. has a 12 month low of $15.40 and a 12 month high of $29.11.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.